Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.
Alberto Lo GulloAndrea BeccioliniSimone ParisiPatrizia Del MedicoAntonella FarinaElisa VisalliYlenia Dal BoscoAldo Biagio Molica ColellaFederica LumettiRosalba CaccavalePalma ScolieriRomina AndraccoFrancesco GirelliElena BraviMatteo ColinaAlessandro VolpeAurora IannielloMaria Chiara DittoValeria NuceraVeronica FranchinaIlaria PlatéEleonora Di DonatoGiorgio AmatoCarlo SalvaraniSimone BernardiGianluca LucchiniFrancesco De LuciaFrancesco Molica ColellaDaniele SantilliNatalia MansuetoGiulio FerreroAntonio MarchettaEugenio ArrigoniRosario FotiGilda SandriVincenzo BruzzeseMarino ParoliEnrico FusaroAlarico ArianiPublished in: Journal of clinical medicine (2023)
Eph and Dph PsA patients treated with apremilast experienced a significant improvement in enthesitis and dactylitis activity. After 1 year, enthesitis and dactylitis remission was achieved in more than one-third of patients.